Revvity, Inc.

The filing shows a company with growing revenue and a balance sheet that has been deleveraging, but with thinner earnings conversion than the top line suggests. Long-term debt fell to $2.63 billion from $3.15 billion, which management ties to repayment of senior unsecured notes that matured in September 2024; total equity was $7.25 billion against $12.17 billion in assets. Operating cash flow was $582.93 million, down from $628.3 million, and the operating cash flow to net income ratio of 2.42 is high partly because net income was reduced by items below operating income. The forensic scores should be read individually. The Beneish M-Score of -2.462 is not in the elevated manipulation-risk zone, which means it sits below the -1.78 screening line; this is a screen result, not proof either way. The Altman Z-Score of 3.86 is in the safe zone for this model, which indicates low near-term distress risk on that measure only. The Piotroski F-Score is 6 of 8 computable signals. The Fog Index of 14.98 is in the hard-to-read band. Segment detail adds nuance: Life Sciences operating income was $458.3 million, but its operating margin fell 139 basis points to 32.0%. The effective tax rate was 10.6%, supported by $24.0 million of federal tax credits. Risk factors highlight FDA regulation, government contracting rules and healthcare compliance laws, where failures could bring fines, recalls or license losses. Readers may want to look at the tariff mitigation discussion, the interest and other expense table, and the restructuring note together.

Catalyst.Revenue rose $101.1 million, or 4%, to $2,856.1 million in fiscal 2025. The MD&A credits Diagnostics, up $68.5 million, or 5%, to $1,424.9 million, led by Immunodiagnostics (+$41.3 million) and Reproductive Health (+$27.2 million). Life Sciences grew $32.5 million, or 2%, to $1,431.1 million, driven by Software (+$35.6 million). Management cites a foundation for 'long-term growth, margin expansion and robust cash flow generation,' but gross margin fell about 104 basis points to 54.8%, which management attributes to tariffs, currency and product mix.

Hidden risk.Net income fell to $241.2 million from $270.38 million, about 11% lower, even though operating income rose to $356.63 million from $346.74 million. The gap sits in interest and other expense, net, which was $88.358 million versus $30.615 million; that line includes an $11.456 million fair-value investment loss and $14.949 million of foreign exchange losses and other expense. Restructuring and other costs more than tripled to $55.9 million from $17.5 million, with about 5% of the workforce affected. The Fog Index of 14.98 places the MD&A in the hard-to-read band, so these items are easy to miss.